Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: Overall and TNF-inhibitor-naïve population results from a 48-week Phase 2b randomized study - 22/08/19
Joseph F. Merola, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA; Arthur Kavanaugh, UC San Diego School of Medicine, La Jolla, CA; Georg Schett, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany; Jose U. Scher, Department of Medicine, NYU Langone Medical Center, New York, NY; Richard B. Warren, The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, UK; Deepak Assudani, UCB Pharma, Slough, UK; Thomas Kumke, UCB Pharma, Monheim am Rhein, Germany; Barbara Ink, UCB Pharma, Slough, UK; Iain McInnes, University of Glasgow, Glasgow, UK; Christopher Ritchlin, University of Rochester Medical Center, Rochester, NY
Le texte complet de cet article est disponible en PDF.| Medical writing support was funded by UCB Pharma. |
Vol 81 - N° 4S1
P. AB48 - octobre 2019 Retour au numéro
Article précédent
- Drug-induced vasculitis: Clinical, histopathologic findings, and prognostic outcomes. A cross-sectional study in the inpatient setting
- Dupilumab for the treatment of adult atopic dermatatis patients in routine clinical practice
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?